UK details medtech spending in NHS Plan delivery report
This article was originally published in Clinica
Executive Summary
The UK National Health Service spent almost £54.5bn ($86bn) in 2002-03, up £5.2bn on the previous year, and plans to spend almost £1bn more on staff and equipment in 2003-04. According to Delivering the NHS Plan: Expenditure Report, published earlier this month, the benefits of last year's spending include new cardiac diagnostic and treatment equipment worth £35m; work on more than 40 cardiac catheterisation laboratories (£20m); the installation of 680 public-access automatic external defibrillators (AEDs); and extending the breast cancer screening programme to cover a further 120,000 women since April 2002.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.